"OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology platforms to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide
results in hours instead of days."

"It currently takes days to test a patient sample to find out if they have an infection, what they
are infected with and to which drugs that infection might be susceptible. This can lead to a
delay in treatment or the wrong treatment being prescribed. According to the Centers for
Disease Control and Prevent"  

 

Entsprechende Reaktion scheint sich anzubahnen :-)  

OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland
https://ir.opgen.com/news-releases/...0k-summary-fda-and-successfully